USVP US Venture Partners

U.S. Venture Partners, known as USVP, is a Menlo Park-based early-stage venture firm with a multi-decade history of leading Series A rounds in cybersecurity, enterprise software, consumer, and healthcare. Currently investing out of USVP XII, the firm operates with a focused mandate to be the lead Series A investor in companies based in the US or Israel across four core sectors, with healthcare, including digital health, as one of the four pillars. The healthcare practice spans medical devices, biotechnology, and IT-enabled healthcare services, with a stated focus on therapeutic medical devices that enable new or less invasive procedures, molecularly targeted protein and small molecule therapeutics, and IT-enabled healthcare services that improve quality and reduce cost.

The firm’s healthcare track record includes notable medical device franchises and digital health platforms, with portfolio companies and prior exits including HeartFlow (the AI-driven cardiac imaging platform that went public via SPAC), Inari Medical (peripheral vascular interventions, IPO and acquisition by Stryker), Inspire Medical Systems (sleep apnea neurostimulation, IPO), Intersect ENT (sinus drug delivery, acquired by Medtronic), Omada Health (digital chronic disease platform), Carrot Fertility (employer fertility benefits), and HealthJoy (employer benefits navigation). The firm’s medical device franchise is particularly notable; few generalist venture firms have produced as many successful FDA-cleared device companies as USVP across the past two decades.

The partnership runs as a relatively small senior team with general partners across the firm’s four sectors. The healthcare team has historically been led by senior general partners with operating and venture backgrounds, including Casey Tansey, who has anchored healthcare and life sciences for many years, and a broader bench of partners and principals across medical devices, biotech, and digital health. The firm’s distinctive operational asset is its deep medical device and surgical-tech expertise, which translates into the kind of regulatory, manufacturing, and commercial pattern matching that few digital-health-only firms can offer.

USVP typically writes initial Series A checks of $5 million to $15 million, with the capacity to lead and to follow on into Series B and C. The firm is decisively a Series A specialist; it does not typically lead seed rounds and does not write growth-stage checks. USVP almost always takes a board seat at the rounds it leads and reserves heavily for follow-on. Geographic scope is United States and Israel, with a particularly strong Israeli network density in medical devices and digital health.

Founders who should approach USVP are Series A-stage operators building medical devices, biotechnology, and IT-enabled healthcare services with a clear regulatory pathway and meaningful early commercial or clinical proof. The firm is particularly well suited for medical device founders who need a lead investor with deep regulatory and manufacturing pattern matching, and for digital health founders building enterprise software for providers, payers, employers, and benefits ecosystems. Repeat operators with prior healthcare exits will find a particularly receptive audience. Founders at seed or pre-seed, founders building consumer DTC brands, and founders without a clear regulatory or commercial wedge should pitch other firms. Founders who want a passive growth check should also look elsewhere; USVP is built for active early-stage partnership.

Entry path runs through warm introductions from portfolio CEOs, peer venture firms, and the Bay Area and Israeli operator networks. The senior team is at JPMorgan Healthcare, BIO, HLTH, ViVE, AdvaMed, and the major medical device and digital health conferences. Cold inbound through the website is triaged. Diligence is rigorous and partner-driven, with substantial clinical and regulatory review for medical device deals, typically four to eight weeks from first meeting to term sheet.

In a pitch, lead with the clinical or commercial wedge, the regulatory pathway, the IP estate, and the team. USVP partners are operationally experienced and they will probe your manufacturing strategy, your reimbursement plan, your commercial sales motion, and your team in detail. For medical device founders, bring a clear FDA strategy and a credible plan from clearance through commercial scaling. For digital health founders, bring a clear enterprise sales motion and unit economics. The firm’s added value is most powerful when founders use the deep USVP network: medical device manufacturing partners, regulatory advisors, and the firm’s strong Israeli ecosystem connections. Founders building Series A-stage healthcare companies with a regulatory or commercial wedge will find USVP one of the more operationally rigorous and useful tier-one Series A partners across both US and Israeli healthcare deals.